Evidence map›Paper›PMID 35563828›Full record

ArticleCells2022

Notch2 Blockade Mitigates Methotrexate Chemotherapy-Induced Bone Loss and Marrow Adiposity.

Yaser Peymanfar, Yu-Wen Su, Cory J Xian

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Yaser PeymanfarUniSA Clinical and Health Science, City West Campus, University of South Australia, GPO Box 2471, North Terrace, Adelaide, SA 5001, Australia.ORCID 0000-0002-5793-0474
Yu-Wen SuUniSA Clinical and Health Science, City West Campus, University of South Australia, GPO Box 2471, North Terrace, Adelaide, SA 5001, Australia.
Cory J XianUniSA Clinical and Health Science, City West Campus, University of South Australia, GPO Box 2471, North Terrace, Adelaide, SA 5001, Australia.ORCID 0000-0002-8467-2845
University of South Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Childhood cancer methotrexate (MTX) chemotherapy often causes bone growth impairments, bone loss, and increased risks of fractures during or after treatment, for which the pathobiology is unclear and there is a lack of specific treatment. Our time course analyses of long bones from rats receiving intensive MTX treatment (mimicking a clinical protocol) found decreased trabecular bone volume, increased osteoclast formation and activity, increased adipogenesis in the expense of osteogenesis from the bone marrow stromal cells at days 6 and 9 following the first of five daily MTX doses. For exploring potential mechanisms, PCR array expression of 91 key factors regulating bone homeostasis was screened with the bone samples, which revealed MTX treatment-induced upregulation of Notch receptor

Indexed as

Antineoplastic AgentsMethotrexateAdiposityAnimalsBone MarrowRatsReceptor, Notch2X-Ray MicrotomographyAntineoplastic AgentsMethotrexateNotch2 protein, ratReceptor, Notch2bone damagebone recoverycancer chemotherapymethotrexateNotch signallingWnt signalling

Identifiers

PMID35563828
PMCPMC9103078
OpenAlexW4225279975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.